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Abstract: A series of organometallic Au(I) N-heterocyclic carbene 
(NHC) complexes was synthesized and characterized on anticancer 
activity in four human cancer cell lines. The compounds’ toxicity in 
healthy tissue was determined using precision cut kidney slices 
(PCKS) as a tool to determine the potential selectivity of the Au 
complexes ex vivo. All evaluated compounds presented cytotoxic 
activity towards the cancer cells in the nano- or low micromolar 
range. The mixed Au(I) NHC complex - (ter-butylethynyl)-1,3-bis-
(2,6-diisopropylphenyl)-imidazol-2-ylidene gold(I), bearing an alkynyl 
moiety as ancillary ligand, showed high cytotoxicity in cancer cells in 
vitro, while being barely toxic in healthy rat kidney tissues. The 
obtained results open new perspectives towards the design of mixed 
NHC-alkynyl gold complexes for cancer therapy.  
Metals and metal complexes have been used for medicinal 
applications since ancient times. For example, copper was the 
first metal described as sterilizing agent between 2600 and 2200 
B.C. (Smith Papyrus). Furthermore, the Ebers Papyrus from 
1500 B.C. describes the use of copper to reduce inflammation 
and the use of iron to treat anaemia, while approximately at the 
same time, zinc was being used to heal wounds.[1,2] In recent 
years, medicinal inorganic chemistry has become a rapidly 
growing field with a broad range of medical applications for 
inorganic and metal-based compounds, including mineral 
supplements (Fe, Zn, Cu, Se), diagnostics (Gd, Mn, Ba, I), 
antimicrobial (Ag), anticancer (Pt), antiulcer (Bi) and antiarthritic 
(Au) agents, among others.[3,4] 
The interest in developing new metal-containing therapeutic 
compounds increased largely after the success of cisplatin in the 
treatment of solid malignancies.[5] Unfortunately, platinum(II)-
containing compounds present several limitations such as 
toxicity in healthy tissues, restricted spectrum of activity and 
development of resistance.[5,6]  
Subsequently, an extensive number of metal-containing 
compounds were described with interesting cytotoxic activities, 
displaying diverse mechanisms of action and pharmacological 
profiles.[7–10] Within this framework, gold-based complexes are 
particularly interesting due to their different possible oxidation 
states (e.g. Au(I) and Au(III)), stability and ligand exchange 
reactions, which confer them different mechanisms of activity 
compared to cisplatin. [4,11,12]  
Early studies on the anticancer activity of the Au(I) complex 
auranofin ([Au(I)(2,3,4,6-tetra-O-acetyl-1-(thio-S)--D-
glucopyranosato)(triethylphosphine)]), presently used in the 
clinic to treat severe rheumatoid arthritis, revealed activity levels 
similar to cisplatin in vitro,[13] which subsequently led to a large 
number of Au(I) complexes being evaluated for antiproliferative 
effects. 
Interestingly, most of the anticancer gold complexes reported so 
far, appear to exert their activity via the interaction with protein 
targets,12–14 and only in a few cases DNA binding has emerged 
as a likely route to cancer cell death.15,16 
Among the various families of gold compounds tested for their 
anticancer effects in the last decade, a variety of organometallic 
gold(I/III) N-heterocyclic  carbene (NHC) complexes were 
designed, featuring anticancer activity in the micromolar or sub-
micromolar range in vitro.[17–21] Specifically, gold(I) NHC 
derivatives exert their effects via different pathways, including: (i) 
mitochondrial damage (common for cationic gold(I) biscarbene 
complexes, which behave as delocalized lipophilic cations (DLC) 
being able to accumulate selectively inside the mitochondria of 
cancer cells due to their higher mitochondrial membrane 
potential), 21–24  (ii) inhibition of the seleno-enzyme thioredoxin 
reductase,[26–28] (iii) inhibition of protein tyrosine phosphatases 
(PTP)[29] and (iv) stabilization of DNA G-quadruplexes.[30–32] 
Moreover, gold(I) NHC complexes are appealing from a 
synthetic point of view due to their high stability with respect to 
ligand exchange reactions, relatively easy synthetic procedures, 
possibility of functionalization leading to increased structural 
diversity, as well as tuneable lipophilic-hydrophilic properties to 
enhance biological activity.[11,19,33,34]  
Therefore, herein we report the synthesis of four Au(I) NHC 
complexes (1-4) (Figure 1) including: mono- (1) and bis-NHC (2) 
compounds featuring a 1-butyl-3-methyl-imidazol-2-yilidene 
ligand. This ligand was chosen to obtain gold complexes 
possessing favourable lipophilicity, in line with previous 
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studies.[33] Based on the same NHC scaffold, an auranofin-type 
complex (3) was obtained, where the NHC moiety replaces the 
phosphane ligand. Moreover, a mixed NHC-alkynyl complex (4) 
was synthesized, with a 1,3-bis-(2,6-diisopropylphenyl)-imidazol-
2-ylidene ligand. The latter was chosen since it was impossible 
to stabilize the mixed NHC-alkynyl metal complexes using the 1-
butyl-3-methyl-imidazol-2-yilidene ligand.   
It should be noted that, recently, Au(I) complexes of the type 
(alkynyl)Au(I)(phosphane), containing an anionic alkynyl group 
as well as a neutral phosphane ligand, have been shown to 
possess interesting anticancer effects in vitro and in vivo. [35,36] 
However, to the best of our knowledge the anticancer properties 
of mixed NHC-alkynyl Au(I) complexes have not been reported 
so far.  
Finally, for comparison purposes and to evaluate the effect of 
the metal ion on the biological activity, the Pt(II) (5) analogue of 
2 was also synthesized. 
The biological activity of our series of Au(I) NHC complexes was 
evaluated both in vitro and ex vivo. Specifically, the cytotoxicity 
of the compounds was tested in four cancer cell lines, namely a 
p53 wild-type and a p53 null variant of HCT 116 (colorectal 
carcinoma), MCF-7 (breast adenocarcinoma) and A375 
(malignant melanoma). Additionally, the new compounds were 
tested for their toxicity on healthy rat kidney tissue ex vivo using 
precision cut kidney slices (PCKS).[37] In PCKS, all cells remain 
in their natural environment maintaining the original cell−cell and 
cell−matrix contacts, which are absent in classical 2D cell 
cultures in vitro[37,38]. This technique is an FDA-approved model 
for drug toxicity and metabolism studies.[37,38] Recently, we have 
successfully used the precision cut tissue slices technique to 
study the toxic effects of experimental anticancer organometallic 
compounds,[31,39,40] aminoferrocene-containing pro-drugs,[41] 
ruthenium-based kinase inhibitors,[42] as well as supramolecular 
metallacages as possible drug delivery systems.[43]  
 
 
Figure 1. Structure of the reported metal NHC complexes. 
 
Synthesis and characterization  
The carbene (1-butyl-3-methyl-imidazol-2-
yilidene)gold(I)chlorido Au(BMIm)Cl (1) and the bis-carbene 
bis(1-butyl-3-methyl-imidazole-2-yilidene)gold(I) 
hexafluorophosphate [Au(BMIm)2]PF6 (2) were synthetized 
according to previously reported procedures,[34] and adapted 
established protocols.[33,44] Thus, synthesis of compound 1 was 
achieved by a transmetalating route from the correspondent 
Ag(I) carbene. 
Compound 2 was synthetized by reaction of Au(SMe2)Cl with 2 
equiv. of 1-methyl-3-butyl-2-ylidene, prepared in situ by 
deprotonation of the correspondent imidazolium salt with 
LiHMDS.  
Complex 3 is a new analogue of auranofin bearing thio-β-
glucose-tetraacetate as ancillary ligand while replacing the 
phosphine with the NHC carbene ligand. The compound was 
obtained in high yields by adapting a procedure previously 
published by Baker et al.[45] that allows the substitution of a 
chlorido ligand using K2CO3 in CH2Cl2. The compound was 
found to be soluble in chlorinated solvents (dichloromethane and 
chloroform), in acetone and in DMSO. This new gold(I) complex 
was characterized in solution by 1H and 13C NMR in CDCl3 
(Figures S1 and S2 in the Supplementary material). The signals 
are consistent with the ones reported for similar compounds, 
confirming the proposed structure.[33,44] 
The most diagnostic feature in the 13C NMR spectrum of 
compound 3 (Figure S2) is the carbene carbon signal at 183.7 
ppm, which shows a downfield shift compared with the signal at 
171.9 ppm of the corresponding precursor 1 with chlorido as 
ancillary ligand, most likely due to the better donating ability of 
the thiolate ligand.[44] The signal of the thiol carbon (C1’) shows 
a downfield shift from 78.9 ppm to 83.0 ppm as a consequence 
of the coordination to the gold(I) centre. In the 1H NMR 
spectrum (Figure S1) the coordination of the thiolate is 
confirmed by the absence of the S-H resonance. In FT-IR 
spectrum the most diagnostic feature is the band of the 
carbonyls at ṽ = 1744 cm-1. (Figure S3). 
Preparation of the gold(I) alkynyl compound 4 was performed 
according to already established procedures,[46,47] by reacting 
3,3-dimethyl-1-butyne with the precursor gold(I) NHC carbene 
(Au(IPr)Cl) in presence of a strong base (ButOK) in MeOH. The 
compound was characterized in solution by 1H and 13C NMR in 
CDCl3 (Figure S4 and S5). The 13C NMR spectrum is featured 
by the signal of the carbene carbon at low field (δ= 191.9 ppm). 
Furthermore, the quaternary carbons of the alkynyl moiety are 
downfield shifted (δ= 114.1 and 112.5 ppm) compared to the 
signals in the precursor (δ= 92.7 and 66.5 ppm) owing to the 
coordination to gold(I). In the 1H NMR he signal of the four 
isopropyl protons is a diagnostic feature, featuring a septet at 
2.60 ppm as well as the corresponding doublets of the methyl 
groups at 1.34 and 1.18 ppm. Another characteristic feature of 
the spectrum is the singlet of the three methyl groups of the 
alkynyl moiety at 1.10 ppm. In the FT-IR spectrum the weak 
band of the triple bond at ṽ = 2116 cm-1 can be recognized 
(Figure S6). 
Compound 5 is a platinum(II) derivative bearing the same NHC 
ligand of compounds 1, 2, 3. It was synthesized by 
transmetalating routes from the correspondent Ag(I) carbene by 
adapting previously reported procedures.[48] Thus, 5 was 
obtained by refluxing Ag(BMIm)Cl with 0,5 eq of K2PtCl4 in 
CH2Cl2 for 4 days. 
The 1H NMR spectrum of 5 in CDCl3 (Figure S7) shows the 
superposition of two sets of signals (shifted of δ~ 0.03 ppm) due 
to the presence of two isomers. 195Pt NMR spectrum confirms 
the presence of two complexes in which the metal nucleus 
resonates at close chemical shifts (δ = -3177.8; -3179.0 ppm) 
(Figure S8). The nature of the isomers can be better elucidated 
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through 13C NMR spectrum (Figure S9). It suggests the 
presence of the two rotamers trans-syn and trans-anti as 
frequently observed for nickel(II) and palladium(II) complexes of 
two unsymmetrical NHC ligands.[49–51] As a matter of fact, only 
one carbenic carbon signal at chemical shift typical of trans-
bis(NHCs)PtX2 complexes is present (δ= 167.3 ppm).[48] The 
formation of the cis isomer can therefore be excluded, since it 
would have given a carbenic carbon signal at significantly upfield 
shifted chemical shift as reported for similar compounds (δ~132-
150 ppm).[52,53]  
The stability of gold compounds 3 and 4 was monitored by 1H 
NMR spectroscopy of mixtures of water and DMSO-d6 during 7 
days at room temperature. The complexes were found to be 
stable in solution in these conditions (Figures S10-S11).  
Moreover, the two complexes were reacted with 1.5 equivalents 
of DL-homocysteine, as an intracellular model nucleophile, in 
CD3OD. 1H NMR spectra revealed that no reaction with 3 
occurred after 24 h. Indeed, neither the signals of the complex 
nor of homocysteine showed any variation (Figures S12-14). 
On the contrary, 4 was found to react with homocysteine with 
the formation of a new species that could be identified as the 
product of the substitution of the alkyne with the thiol. Indeed, a 
series of 1H NMR spectra registered during 24 h shows the 
progressive conversion of 4 into a new complex (Figure S15), 
most likely involving coordination of the amino acid to the gold 
centre with substitution of the alkynyl moiety. In fact, after 24 h, 
new signals in the region of aromatic protons are visible (from δ= 
7.55, 7.50, 7.36 ppm of the precursor to δ= 7.62 ppm, δ= 7.54, 
7.37 ppm), the signal of one of the doublets of the methyl groups 
in the isopropyl moiety shifted from δ= 1.23 to 1.26 ppm. 
Another relevant feature is the simultaneous progressive 
disappearance of the signal of the methyl groups of the alkyne at 
δ= 1.03 with the formation of a new signal at δ= 1.22 ppm, 
consistent with the presence of a dissociated 3,3-dimethyl-
butyne moiety (Figure S16-S18). Furthermore, the integration of 
the signals of coordinated homocysteine with the ones of the 
NHC moiety let us suppose that only the alkyne was substituted 
by the amino acid nucleophile in these conditions (Figure S19). 
This hypothesis was further confirmed by 13C NMR spectrum of 
the mixture after 24 h, where the carbenic carbon signal is still 
present (δ= 173.7 ppm) (Figure S20). 
 
In vitro cell viability assays 
The antiproliferative properties of the Au(I) NHC complexes 1−4 
and of cisplatin and auranofin as comparison, were assessed 
using the MTT assay in the human cancer cell lines HCT116 
p53 wt, HCT116 p53 null, MCF-7 and A375.  
All the tested Au(I) complexes presented antiproliferative effects 
in the evaluated cell lines in the lowM range (Table 1). Instead, 
the Pt(II) complex 5 was scarcely active (EC50  50 μM). The 
latter result is in accordance with other studies on Pt(II) bis-NHC 
complexes with chlorido ligands (see ref 20 and citations 
therein) featuring moderate cytotoxic effects in vitro. Notably, the 
compounds 1, 2 and 3 showed superior activity, in the nM or low 
μM range, compared with cisplatin and auranofin in three of the 
four cell lines, A375 being the exception. Overall, no significant 
differences could be observed between the EC50 values for the 
mono-carbene (1), bis-carbene (2), and auranofin-analogue (3) 
in the different cancer cell lines. Interestingly, the alkynyl 
derivative (4) was effective although ca. 4-10 fold less potent 
compared to the other gold NHC complexes. However, in 
general 4 was markedly more active or as active as cisplatin, 
except in the A375 cell line. Additionally, the lack of differences 
observed between the HCT116 p53 wt and p53 null cells treated 
with the gold complexes indicates that their toxicity mechanism 
is independent of p53 activity, in contrast to cisplatin. The latter 
is known to induce rapid p53-dependent apoptosis and, as a 
secondary effect, p53-independent cell cycle arrest.[54,55] 
 
Table 1. EC50 values of Au(I) NHC complexes in various human cancer cell 
lines, in comparison to auranofin and cisplatin, after 72 h incubation. 
 
EC50a (µM) 
Compound 
HCT116  
p53wt 
HCT116 
p53null 
MCF-7 A375 
1 0,5 ± 0,3 0,6 ± 0,2 0,8 ± 0,4 2 ± 1 
2 0,6 ± 0,4 0,24 ± 0,09 1,1 ± 0,3 1,0 ± 0,6 
3 0,8 ± 0,2 1 ± 0,4 2 ± 0,8 1,2 ± 0,2 
4 9 ± 3 8,8 ± 0,9 6 ± 2 10 ± 1 
5 > 50 > 50 > 50 ND 
auranofin 5,1 ± 0,7 7,10 ± 0,01 7 ± 2 1,3 ± 0,8 
cisplatin 11 ± 3 20,6 ± 0,9 12 ± 2 3,7 ± 0,9 
a The reported EC50 values were calculated using a nonlinear fitting of 
log[concentration] vs response and are presented as a mean (± SD) of at least 
three independent experiments. ND: not determined. 
 
Ex vivo toxicity evaluation 
Due to their potent cytotoxic effects in cancer cells, complexes 
1-4 were tested for their possible toxicity in an ex vivo model in 
healthy rat kidney tissue using the PCKS technology.[37,38]  
Kidney was selected since cisplatin is well known to induce 
severe nephrotoxicity in patients.[56] 
Hence, kidney slices were incubated with various concentrations 
of each gold complex, and after 24 h the viability of the tissues 
was determined measuring the ATP content (Table 2 and Figure 
2). Auranofin and cisplatin were also tested for comparison. 
The gold complexes, including auranofin, displayed a 
concentration dependent toxicity profile, with complexes 1 and 2 
as the most toxic, with TC50 below 1 µM. Interestingly, 
compounds 1-3 were more toxic than cisplatin (ca. 6-12-fold). 
Remarkably, complex 4 showed no toxicity up to 50 µM. For 
compounds 1-3 the safety margin for toxicity was small to 
absent with a ratio of TC50 PCKS/EC50 cells between 0,4 and 3,3. 
However, for compound 4 the TC50 PCKS/EC50 cells ratio cells 
was higher than 5,0 to 8,3 indicating selective toxicity towards 
cancer cells compared to healthy kidney tissue. 
The differential effects of complexes 1 and 4 (5 µM 
concentration) on kidney slices were further assessed by 
histomorphology using Periodic acid-Schiff staining (PAS) to 
evaluate slice integrity and particularly to visualize the basement 
membranes and epithelial brush border in the proximal tubule 
cells, as reported in the experimental section. After 24 h 
incubation, the untreated kidney slices show minor 
morphological changes, indicated by pyknosis and swelling of 
some of the tubular cells (Figure 3A). Marked effects were 
observed upon treatment with complex 1, which induced 
dilatation of Bowman’s space in the glomerulus and necrosis of 
the distal tubule cells, as well as discontinuation of the brush 
border in the proximal tubule cells at some sites (Figure 3B). In 
contrast, exposure of slices to complex 4 (Figure 3C) did not 
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induce significant morphological changes compared to controls. 
Auranofin treatment led to damage of the distal tubule cells and 
loss of nuclei from the proximal tubule cells. Moreover, cisplatin 
treatment (25 M corresponding to 2-fold the TC50, Figure 3E) 
showed damage to the proximal tubular cells with loss of nuclei 
and discontinuation of the brush border; additionally, damage of 
the distal tubule is evident as previously reported in the 
literature.[57]  
 
Table 2. Toxicity of Au(I) NHC complexes (TC50 values) in PCKS in 
comparison to auranofin and cisplatin.  
 
Compound TC50a (µM) TC50 (PCKS) / EC50 (cells)  
1 0,8 ± 0,3 0,4 - 1,6 
2 0,8 ± 0,7 1,3 - 3,3 
3 2,1 ± 0,4 1,1 - 2,6 
4 > 50 >5,0 - 8,3 
auranofin 2,9 ± 1,4 0,4 - 2,2 
cisplatin 12 ± 6 0,6 - 3,2 
a The reported TC50 values were calculated using a nonlinear fitting of 
log[concentration] vs response and are presented as a mean (± SD) of at least 
three independent experiments.  
 
 
Figure 2. Viability of rat (PCKS) relative to the controls (untreated slices) after 
treatment with complexes 1-4 and auranofin for 24 h. The error bars show the 
standard deviation of at least three independent experiments. We performed 
an ANOVA analysis with each individual experiment as random effect and a 
Tukey HSD post-hoc test for pairwise comparisons.  
 
Figure 3. Morphology of rat kidney slices. A: 24 h control incubation; B: 
complex 1; C: complex 4; D: auranofin; E: cisplatin. The Au(I) complexes were 
incubated at 5 µM concentration for 24 h, while cisplatin at 25 µM for 24 h. PT: 
proximal tubule, DT: distal tubule, G: glomerulus. Scale bar indicates 50 µm. 
Conclusions 
The broad spectrum and synthetic possibilities in organometallic 
chemistry allowed us to develop and study different NHC ligands 
“fine-tuning” the physico-chemical properties of the resulting 
Au(I) complexes, and, possibly, achieving selectivity towards 
cancer tissue.   
Herein, we reported the synthesis of complexes 3 and 4, as a 
continuation of our previous work where we described the 
synthesis and very preliminary biological evaluation of 
complexes 1 and 2.[34] In this study, complexes 1-4 showed 
interesting cytotoxic activity against HCT116 p53 wt and p53 null, 
MCF-7 and A357, in the lowM range. Instead, the Pt(II) 
complex 5 was poorly cytotoxic, indicating the essential role of 
Au(I) ions in the biological activity. However, complexes 1-3 and 
auranofin displayed severe toxicity in healthy kidney tissue 
(PCKS), even higher than cisplatin, indicating that these 
compounds, when administered in vivo, may also induce severe 
nephrotoxicity. Conversely, the mixed NHC and alkynyl complex 
4 appears to be at least 5-fold less toxic in healthy tissue, while 
maintaining antiproliferative effects at the low micromolar 
concentration. The reduced bioactivity of this compound may be 
partly due to its lower stability in the presence of nucleophiles, 
such as sulfur donor ligands. However, the selectivity of 4 for 
cancer cells with respect to healthy tissues is still promising in 
comparison to the other tested Au(I) NHC complexes. This initial 
result prompts us to develop new mixed organometallics with 
enhanced selectivity against cancer cells. Moreover, ongoing 
studies in our labs are aimed at further investigating the 
mechanisms of action of toxicity in cancer cells and kidney slices. 
So far, pilot studies using mass spectrometry (MS) analysis of 
complexes 1-4 showed no reactivity towards model protein 
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targets (cytochrome c and lysozyme), while 1 and 2 could bind 
to the copper chaperon protein Atox-1 upon complete ligand 
loss.[34]  
Overall, we believe that it is important that toxicology studies, as 
those presented here using our ex vivo model, should be 
conducted as early as possible on new experimental 
metallodrugs to select the optimal chemical scaffolds and to 
orient the drug design at its early stages 
Experimental section 
General 
Unless stated otherwise the reactions were performed under 
inert atmosphere of nitrogen in anhydrous conditions. Solvents 
and reagents were used without prior treatments. NMR spectra 
were recorded on a Varian Gemini 200 BB instrument (1H, 200 
MHz; 13C, 50.3 MHz, 195Pt, 42.8 MH) at room temperature; 
frequencies are referenced to the residual resonances of the 
deuterated solvent. UV-visible spectra were recorded on an 
Agilent Cary 60 spectrophotometer. Fourier transform infrared 
spectroscopy (FT-IR) spectra were recorded on a Spectrum One 
Perkin Elmer instrument equipped with an UATR unit.   
 
Synthetic procedures 
The carbenes (1-butyl-3-methyl-imidazol-2-
yilidene)silver(I)chlorido Ag(BMIm)Cl, (1-butyl-3-methyl-imidazol-
2-yilidene)gold(I)chlorido Au(BMIm)Cl (1) and the bis-carbene 
bis(1-butyl-3-methyl-imidazole-2-yilidene)gold(I) 
hexafluorophosphate [Au(BMIm)2]PF6 (2) were synthetized 
according to procedures previously reported by us[34] and their 
purity was confirmed by elemental analysis, and resulted to be > 
98 %.  
Synthesis of thio-β-D-glucose-tetraacetate-(1-butyl-3-methyl)-
imidazol-2-ylidene-gold(I) (3) 
Precursor 1 was reacted with thio-β-D-glucose-tetraacetate to 
prepare compound 3. 0.1 mmol of 1 was dissolved in 15 ml of 
CH2Cl2, 1 mmol of K2CO3 and 0,1 mmol of thio-β-glucose-
tetracetate (tgt) were added to the solution. The suspension was 
stirred at room temperature for 10 min in the dark. The mixture 
was filtered and the solution was concentrated by evaporation to 
about 2 ml. The product was precipitated with hexane and 
washed to obtain a light brown solid (yield > 99%). 
1H NMR (CDCl3, 293K) δ (ppm) = 6.90 (m, 2H, H4 and H5); 5.12- 
5.03 (m, 3H, tgt); 4.25-4.12 (m, 2H, H6, 3H tgt); 3.83 (s, 3H, H10); 
3.76-3.68 (m, 1H, H5’); 2.08 (s, 3H, OAc); 2.02 (s, 3H, OAc); 
1.99 (s, 3H, OAc); 1.96 (s, 3H, OAc); 1.83 (apparent quintet J= 
7.4 Hz, 2H, H7a-b); 1.68 (s, H2O); 1.37 (apparent sextet J= 7.4 Hz, 
2H, H8a-b) ; 1.26 (hexane); 0.96 (t J= 7.4 Hz, 3H, H9); 0.86 
(hexane). 
13C NMR (CDCl3, 293K) δ (ppm) = 183.2 (C2); 170.8 (C=O); 
170.3 (C=O); 169.9 ( C=O); 169.7 (C=O); 121.4 (C4 or C5); 
120.3 (C4 or C5); 83.3 (C1’); 77.9 (C2’); 75.8 (C5’); 74.5 (C3’); 
69.2 (C4’); 63.2 (C6’); 50.9 (C6); 36.1 (C10); 33.4 (C7);31.4 
(hexane); 22.8 (hexane) 21.4 (OAc); 21.0 (OAc); 20.9 (2OAc); 
19.8 (C8); 14.1 (hexane); 13.9 (C9). 
  
IR (solid state): ṽ (cm-1) = 2962 (w-m); 2916 (w); 2870 (vw); 
1744 (m, CO); 1567 (vw); 1469 (w); 1412(w); 1258 (s); 1220 
(m); 1086 (s); 1016 (vs); 911 (w-m); 865 (w-m); 795 (vs); 734 (w-
m); 680 (w-m). Anal. Calc. (%) for C22H33AuN2O9S: C 37.70, H 
4.75, N 4.00; found: C 37.64, H 4.65, N 3.98. 
Synthesis of (ter-butylethynyl)-1,3-bis-(2,6-diisopropylphenyl) 
imidazol-2-ylidene -gold(I) (4) 
The compound was prepared according to previously reported 
procedures.[46,47] The colourless solid was obtained with 80% 
yield. 
1H NMR (CDCl3, 293K) δ (ppm)= 7.48 (t, J= 7.4 Hz, 2H, CH-
aromatic); 7.28 (d, J=7.4 Hz, 4H, CH-aromatic); 7.06 (s, 2H, CH-
imidazole); 2.61 (sept, J= 6.9 Hz, 4H, CH(CH3)2 isopropyl); 1.35 
(d, J= 6.8 Hz, 12H, CH(CH3)2 isopropyl); 1.18 (d, J= 6.8 Hz, 12H, 
CH(CH3)2 isopropyl); 1.10 (s, 9H, C(CH3)3 ter-butylethynyl).  
13C NMR (CDCl3, 293K) δ (ppm) = 191.9 (NCN imidazol); 145.7 
(CH aromatic); 134.7 (C aromatic); 130.4 (CH aromatic); 124.2 
(CH aromatic); 123.2 (CH imidazole); 114.05 (Au-CC); 112.51 
(Au-CC); 32.6 (C(CH3)3 ter-butylethynyl); 28.9 (CH(CH3)2 
isopropyl); 28.3 (C(CH3)3 ter-butylethynyl); 24.5 (CH(CH3)2 
isopropyl); 24.3 (CH(CH3)2 isopropyl).  
IR (solid state): ): ṽ (cm-1) = 3150 (w); 2966 (m/s); 2923 (m, sh); 
2864 (w/m); 2116 (vw, CC); 1956 (vw); 1890 (vw); 1825 (vw); 
1593 (w); 1720 (vw); 1677 (vw); 1650 (vw); 1558 (w); 1458 (s); 
1410 (m); 1387 (w/m); 1364 (m); 1354 (w/m); 1343 (w/m); 1329 
(w/m); 1275 (w); 1249 (m); 1208 (w/m); 1208 (w/m); 1181 (w/m); 
1104 (w/m); 1082 (w/m); 1062 (w/m); 1032 (w); 981 (w); 944 
(m); 805 (s); 764 (s); 731 (s); 697 (s); 561 (w). ESI-MS (DMSO-
MeOH), positive mode exact mass for [C33H46N2Au]+ 
(667.3321): measured m/z 667.3322 [M]+. Anal. Calc. (%) for 
C33H45AuN2: C 59.45, H 6.80, N 4.20; found: C 59.39, H 6.58, N 
4.18. 
Synthesis of trans-dichlorido-bis(1-butyl-3-methyl-imidazole-2-
yilidene)platinum(II) (5) 
161 mg of K2PtCl4 (0,388 mmol) were suspendend in 15ml of 
CH2Cl2, afterwards 218 mg of Ag(BMIm)Cl (0,775 mmol) were 
added. The mixture was refluxed for 4 days and then filtered on 
celite. Solvent was removed under reduced pressure and the 
product was obtained with 86% yield. 
1H NMR (CDCl3, 293K), syn and anti δ (ppm)= 6.80 (m, 2H, 
imidazole); 4.54-4.46 (m, 8H, NCH2CH2CH2CH3); 4.11, 4.08 (s+ 
s, 12H, NCH3); 2.14-1.96 (m, 8H, NCH2CH2CH2CH3); 1.63 
(H2O); 146-1.43 (m, 8H, NCH2CH2CH2CH3); 1.00 (t J2 = 7.3Hz; 
6H, NCH2CH2CH2CH3); 0.99 (t J2= 7.3 Hz, 6H, 
NCH2CH2CH2CH3) 
13C NMR (CDCl3, 293K), syn and anti δ (ppm)= 167.3 (NCN); 
121.3 (s+d, JPt-C= 23.3 Hz, CH imidazole); 120.1 (s+d, JPt-C= 
24.5 Hz, CH imidazole); 50.0 (s+d, JPt-C= 18.9 Hz, 
NCH2CH2CH2CH3); 37.1 (NCH3); 37.0 (NCH3); 33.2 
(NCH2CH2CH2CH3); 20.2 (NCH2CH2CH2CH3); 14.0 
(NCH2CH2CH2CH3); 13.9 (NCH2CH2CH2CH3). 
195Pt NMR (CDCl3, 293K), syn and anti δ (ppm)= -3177.8; -
3179.0. 
 
NMR stability studies in aqueous media and reactivity with 
homocysteine. 
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4·10-3 mmol of 3 were dissolved in 0.4 ml of DMSO-d6/H2O 60:40, 
while 6·10-3 mmol f 4 were dissolved in 0.4ml of DMSO-d6/H2O 
80:20. 1H NMR spectra were registered at various time intervals 
(0h, 24h, 1 week). Afterwards, 5.0·10-3 mmol of 3 or 4.2·10-3 
mmol of 4 were reacted with 1.5 equivalents of DL-
homocysteine in 0.4 ml of CD3OD. Reactions were monitored 
through 1H NMR (0h, 6h, 24 h) and 13C NMR. 
Cell lines 
The human colorectal carcinoma HCT 116 p53 null and HCT 
116 wt p53 variants (kindly provided by Dr. Götz Hartleben, 
University of Groningen), the human breast adenocarcinoma 
MCF-7 (Leibniz-Institut DSMZ - Deutsche Sammlung von 
Mikroorganismen und Zellkulturen GmbH), and human 
malignant melanoma A375 (kindly provided by Prof. Sylvestre 
Bonnet, Leiden University) were cultured in DMEM (Dulbecco’s 
Modified Eagle Medium) containing glutamax supplemented with 
10% FBS and 1% penicillin/streptomycin (all  from Invitrogen), at 
37 °C in an incubator (Thermo Fisher Scientific, US) with 
humidified atmosphere of 95% of air and 5% CO2. 
In vitro cell viability assays 
Cells in an exponential growth rate were seeded (8000 cells per 
well) in 96-wells plates (Costar 3595) grown for 24 h in complete 
medium. Solutions of the gold compounds were prepared by 
diluting a stock solution (10-2 M in DMSO, ethanol in the case of 
auranofin) in culture medium (DMSO or ethanol in the culture 
medium never exceeded 1%). Subsequently, different dilutions 
of the compounds were added to the wells to obtain a final 
concentration from 0.5 to 100 μM. Following 72h of exposure, 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
was added to the cells at a final concentration of 0.50 mg/ml in 
PBS (phosphate buffered saline solution, pH 7.4) and incubated 
for 2.5 h. The incubation medium was removed and the violet 
formazan crystals in the cells were dissolved in DMSO, and the 
optical density of each well was quantified at 550 nm, using a 
multi-well plate reader (ThermoMax microplate reader, 
Molecular devices, US). The percentage of surviving cells was 
calculated from the ratio of absorbance between treated and 
untreated cells. Each treatment was performed in quadruplate. 
The EC50 value was calculated as the concentration causing 
50% decrease in cell number and is presented as a mean (± SD) 
of at least three independent experiments. 
Preparation of rat Precision-Cut Kidney Slices (PCKS) and 
toxicity studies ex vivo 
Male Wistar rats (Charles River, France) of 250-300 g were 
housed under a 12 h dark/light cycle at constant humidity and 
temperature. Animals were permitted ad libitum access to tap 
water and standard lab chow. All experiments were approved by 
the committee for care and use of laboratory animals of the 
University of Groningen and were performed according to strict 
governmental and international guidelines. Kidneys were 
harvested (from rats anesthetized with isoflurane) and 
immediately placed in University of Wisconsin solution (UW, 
ViaSpan, 4⁰C) until further use. After removing fat, kidneys were 
cut in half lengthwise using a scalpel, and cortex cores of 5 mm 
diameter were made from each half perpendicular to the cut 
surface using disposable Biopsy Punches (KAI medical, Japan). 
PCKS were made as described by de Graaf et al..[37,38] The 
cores were sliced with a Krumdieck tissue slicer (Alabama R&D, 
Munford, AL, USA) in ice-cold Krebs-Henseleit buffer, pH 7.4 
saturated with carbogen (95% O2 and 5% CO2). Kidney slices 
weighing about 3 mg (~150 μm thickness), were incubated 
individually in 12-well plates (Greiner bio-one GmbH, 
Frickenhausen, Austria), at 37°C in Williams’ medium E (WME, 
Gibco by Life Technologies, UK) with glutamax-1, supplemented 
with 25 mM D-glucose (Gibco) and ciprofloxacin HCl (10 µg/mL, 
Sigma-Aldrich, Steinheim, Germany) in an incubator (Panasonic 
biomedical) in an atmosphere of 80% O2 and 5% CO2 with 
shaking (90 times/min). Stock solutions of compounds 1 to 4, 
auranofin and cisplatin were prepared as for the studies on cell 
lines.  The final concentration of DMSO and ethanol during the 
PCKS incubation was always below 0.5% to exclude solvent 
toxicity. For each concentration, three slices were incubated 
individually for one hour in WME and subsequently, different 
dilutions of the compounds were added to the wells, to obtain a 
final concentration from 0.5 to 50 μM. After this, PCKS were 
incubated for 24 h. After the incubation, slices were collected for 
ATP and protein determination, by snap freezing them in 1 ml of 
ethanol (70% v/v) containing 2 mM EDTA with pH=10.9. After 
thawing the slices were homogenized using a mini bead beater 
and centrifuged. The supernatant was used for the ATP essay 
and the pellet was dissolved in 5N NaOH for the protein essay. 
The viability of PCKS was determined by measuring the ATP 
using the ATP Bioluminescence Assay kit CLS II (Roche, 
Mannheim, Germany) as described previously.[37] The ATP 
content was corrected by the protein amount of each slice and 
expressed as pmol/μg protein. The protein content of the PCKS 
was determined by the Bio-Rad DC Protein Assay (Bio-Rad, 
Munich, Germany) using bovine serum albumin (BSA, Sigma-
Aldrich, Steinheim, Germany) for the calibration curve. The TC50 
value was calculated as the concentration reducing the viability 
of the slices by 50%, in terms of ATP content corrected by the 
protein amount of each slice and relative to the slices without 
any treatment, and is presented as a mean (± SD) of at least 
three independent experiments.  
Histomorphology 
Kidney slices were fixated in 4% formalin for 24 hours and 
stored in 70% ethanol at 4⁰C until processing for morphology 
studies. After dehydration, the slices were embedded in paraffin 
and 4 μm sections were made, which were mounted on glass 
slides and PAS staining was used for histopathological 
evaluation. Briefly, the glass slides were deparaffinised, washed 
with distilled water, followed by treatment with a 1% aqueous 
solution of periodic acid for 20 minutes and Schiff reagent for 20 
minutes, the slides were rinsed with tap water, finally, a 
counterstain with Mayer’s haematoxylin (5 min) was used to 
visualize the nuclei. 
Statistics 
A minimum of three independent experiments were performed 
with the cells, with 4 replicas for each condition. PCKS were 
prepared from 3 rats and in each experiment slices were 
exposed in triplicate. The EC50 and TC50 values were calculated 
as the concentration reducing the viability of the cells or slices 
by 50%, relative to the untreated samples using a nonlinear 
fitting of log[concentration compound] vs response and is 
presented as a mean (± SD) of at least three independent 
experiments. Statistical testing was performed with one way 
ANOVA with each individual experiment as random effect. We 
performed a Tukey HSD post-hoc test for pairwise comparisons. 
In all graphs and tables the mean values and standard deviation 
(SD) are shown. 
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A novel series of gold(I) N-heterocyclic carbene (NHC) have been prepared and characterized. The antiproliferative activities of the 7 
compounds were tested in four human cancer cell lines and their toxicity in healthy tissue was determined using precision cut kidney 8 
slices (PCKS) showing interesting activities in both in vitro and ex vivo models.  9 
